Summary：**Piramal Pharma Emerges as Must‑Buy Stock Amid Today's Sensex Surge**Indian equity markets logged a

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Piramal Pharma Emerges as Must‑Buy Stock Amid Today's Sensex Surge**

Indian equity markets logged a sharp rally today, with the Sensex climbing over 300 points and the Nifty breaching the 22,500 mark. Amid the broad‑based buying, Piramal Pharma Ltd. has caught the eye of traders and analysts alike, posting a steady gain of 4.2% to trade near ₹158. The stock’s recent price action, underpinned by a solid technical base, has prompted several brokerage houses to flag it as a “must‑buy” opportunity.

**Key Developments**
Piramal Pharma found decisive support at ₹132 in early March, a level that held firm despite a modest pull‑back in May and June. Since then, the share price has carved out a series of higher lows, forming a classic ascending triangle pattern on the daily chart. Volume analysis shows a noticeable uptick in buying interest during the last two sessions, with institutional participation rising by roughly 18% compared to the previous week. The company’s latest quarterly results, released last Thursday, revealed a 9% year‑on‑year increase in revenue driven by strong performance in its generic formulations and over‑the‑counter segments. Management also reiterated its guidance for FY25, citing upcoming product launches in the biosimilar space and a robust pipeline of niche APIs.

**Industry Analysis**
The Indian pharmaceutical sector is currently benefiting from a dual tailwind: domestic demand for affordable